- In March 2021, Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, announced that it received approval from the U.S. Food and Drug Administration (FDA) for PONVORY (ponesimod) as a treatment for multiple sclerosis. This approval marks a significant advancement in the available therapies for managing this chronic condition. With PONVORY now authorized for use, patients have access to a new option that may enhance their treatment outcomes and improve their quality of life
- In March 2021, Genentech announced that it received approval from the U.S. Food and Drug Administration (FDA) for the subcutaneous injection of Actemra (tocilizumab) to treat systemic sclerosis-associated interstitial lung disease. This approval represents a significant milestone in expanding treatment options for patients suffering from this challenging condition. With Actemra now available in a subcutaneous form, it offers a more convenient administration route, potentially improving adherence and patient outcomes
Frequently Asked Questions
The market is segmented based on Global Scleroderma (Systemic Sclerosis) Treatment Market Segmentation, By Type (Limited and Diffuse), Indication (Systemic and Localized), Therapeutics (Immunosuppressant, Calcium-Channel Blockers, Endothelin Receptor Antagonists, PDE-5 Inhibitors, Prostacyclin Analogues, and ACE Inhibitors) – Industry Trends and Forecast to 2032
.
The Global Scleroderma Systemic Sclerosis Treatment Market size was valued at USD 532.49 USD Million in 2024.
The Global Scleroderma Systemic Sclerosis Treatment Market is projected to grow at a CAGR of 10.8% during the forecast period of 2025 to 2032.
The major players operating in the market include , Actelion Pharmaceuticals Ltd , F. Hoffmann,La Roche Ltd , Bristol,Myers Squibb Company , Boehringer Ingelheim International GmbH , Allergan , GlaxoSmithKline plc , Biogen , Novartis AG , Teva Pharmaceutical Industries Ltd , AstraZeneca , CELGENE CORPORATION , ONO PHARMACEUTICAL CO. , Aspen Holdings , H.A.C. PHARMA , Pfizer , Eli Lilly and Company , Bayer AG , Argentis Pharmaceuticals LLC , Inventiva , Amgen , Corbus Pharmaceuticals Holdings , Sanofi , Cumberland Pharmaceuticals ,.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
